Clinical Impact of Dedicated MR Staging of Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Other: MRI
- Registration Number
- NCT03399344
- Lead Sponsor
- The Netherlands Cancer Institute
- Brief Summary
The only chance of cure for patients with advanced stage ovarian cancer is complete cytoreductive surgery (CRS). The only way to determine whether complete CRS can be achieved is by a laparoscopy. However, diffusion-weighted magnetic resonance imaging (DW-MRI) has a very high sensitivity to detect small volume malignant disease, making it a potentially suitable staging tool. Aim of this study is to determine the performance of DW-MRI for predicting whether complete CRS can be achieved.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 270
- Patients with advanced stage (FIGO stage III or IV) ovarian cancer scheduled for primary or interval cytoreductive surgery
- Age >18 years
- Written and signed informed consent
- WHO 0-2
- Able to read and write Dutch
- Patients with contraindications for MRI
- Patients with contraindications for CRS
- Known additional malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description DW-MRI MRI Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
- Primary Outcome Measures
Name Time Method Diagnostic performance of DW-MRI to predict a complete cytoreductive surgery 1 month Patients will undergo an additional MRI, besides their regular diagnostic workup, for assessing the extent of peritoneal carcinomatosis. Whether or not complete cytoreductive surgery is feasible will be determined on DW-MRI independently by two radiologists. The outcome wil be defined as the number of cytoreductive procedures correctly predicted by DW-DWI.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
NKI-AVL
🇳🇱Amsterdam, Netherlands